Dermapharm Holding SE

Last week, our 2024 Annual General Meeting took place in Grünwald near Munich. During the AGM, the Management Board gave a comprehensive overview of our strong financial and operational performance in 2023, and confirmed the outlook for 2024. The AGM resolved the dividend distribution of EUR 0.88 per share with a distribution ratio of approximately 78% of consolidated net profit. Please find the complete corporate news here: https://lnkd.in/d7G7EvJZ

Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy! » Robust, double-digit organic growth in high-margin "branded pharmaceuticals" largely offsets projected decline in vaccine production » Consolidated revenue falls as projected by 6.4% year on year to EUR 298.7 million » Board of Management confirms outlook for 2024 overall, continues to expect consolidated revenue of EUR 1,170–1,210 million and adjusted EBITDA of EUR 305–315 million Read the full Q1 quarterly statement on our website: https://lnkd.in/e6eDwaUK

Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges! Our full year results for fiscal year 2023 have been published today: » Consolidated revenue up year on year by 10.8% to EUR 1,135.4 million » Adjusted consolidated EBITDA declines 13.8% to EUR 310.2 million » Adjusted consolidated EBITDA margin at 27.3% » Earnings decline as boom from vaccine business fades » Dividend proposal of EUR 0.88 per share for 2023 » Further revenue and EBITDA growth expected in 2024 Read the Annual Report 2023 on our website: https://lnkd.in/e6eDwaUK

Dermapharm continues its growth strategy!   Our preliminary full year results for fiscal year 2023 have been published today: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business   >> Consolidated revenue grows by 10.8% compared to previous year to a record EUR 1.1 bn >> Adjusted consolidated EBITDA of EUR 310.2m resulting in an adjusted consolidated EBITDA margin of 27.3% >> Board of Management proposes dividend of EUR 0.88 per share at Annual General Meeting >> Strengthening of “Other Healthcare products” segment >> Further revenue and EBITDA growth expected in 2024 You can also find the Corporate News in German and English on our website: https://lnkd.in/e6eDwaUK

Last week, Christof Dreibholz, Britta Hamberger and Ann-Cathrin Drewes represented the Dermapharm Group at the Berenberg European Conference. As has been the case for many years, the conference took place at the wonderful Pennyhill Park Hotel near London. For us, this was the last conference in 2023 and therefore a crowning finale. We greatly appreciate the many insightful discussions we had and the excellent organisation by Berenberg.

Christof Dreibholz and Britta Hamberger just returned from 2023 Jefferies Healthcare Conference in London. Thank you for the organisation and the interesting meetings we had.

Dermapharm Holding SE builds on success in Q3 2023: Our Q3 financial results show strong organic growth of the diversified product portfolio and the successful acquisition of the Arkopharma Group. » Consolidated revenue and EBITDA (adjusted) stay on course, climbing to EUR 866.6 million and EUR 243.8 million, respectively » Adjusted consolidated EBITDA margin at 28.1% » Board of Management confirms outlook for 2023 and expects revenue and adjusted EBITDA at upper range of forecast Read the full Q3 quarterly statement on our website: https://lnkd.in/e6eDwaUK

Yesterday we welcomed our analysts, investors and banks at Arkopharma in Carros / Nice. Besides an overview of Dermapharm by Dr. Andreas Eberhorn and a financial update on Dermapharm's current trading by Christof Dreibholz, the event provided deep insights into Arkopharma's business with comprehensive details on the product portfolio, the competitive landscape and its USP, followed by innovation and business opportunities from R&D, ESG initiatives, regional and international activities as well as synergies and financials. The event was rounded off with a factory tour.

We are looking forward to our Capital Markets Day 2023: The capital markets day will provide insights into Arkopharma and its integration into the Dermapharm Group including a guided factory tour. Founded in 1980 in Carros, in the Alpes-Maritimes, Arkopharma is a European leader in natural OTC with a broad portfolio of well-established products across key therapeutic areas. Since January 2023 Arkopharma is part of the Dermapharm Group. 

Dermapharm launcht neue Karriereplattform Wir freuen uns, Ihnen unsere konzerneinheitliche Karriereplattform vorzustellen! 🚀 Bei Dermapharm suchen wir nicht nur nach Mitarbeitern, sondern nach visionären Köpfen, die unsere Leidenschaft für Innovation und Exzellenz teilen.   🔍 Entdecken Sie Ihre Möglichkeiten! Unsere neue Karriereplattform bietet:   ✨ Vielfältige Chancen: Von Forschung und Entwicklung bis hin zu Marketing und Vertrieb – wir haben Positionen für verschiedene Fachgebiete. ✨ Karriereentwicklung: Bei uns können Sie nicht nur einen Job finden, sondern auch eine langfristige Karriere aufbauen. ✨ Innovative Projekte: Arbeiten Sie an wegweisenden Projekten, die einen echten Einfluss auf die Gesundheitsbranche haben.   🌱 Warum Dermapharm Gruppe? Unsere Unternehmenskultur fördert Kreativität, Teamarbeit und kontinuierliches Lernen. Wir glauben daran, dass unsere Mitarbeiter der Schlüssel zu unserem Erfolg sind, und investieren in ihre berufliche Entwicklung und Zufriedenheit.   🔗 Sind Sie bereit, Teil unseres Teams zu werden? Besuchen Sie unsere neue Karriereplattform und entdecken Sie, wie Sie Ihre Karriere bei der Dermapharm Gruppe beginnen können: https://lnkd.in/eYntC9rc   #Karriere #Innovation #DermapharmGruppe #JetztBewerben #ZukunftGestalten